Long-Term Efficacy of Dapagliflozin as Add-On to Metformin (MET) in T2DM Inadequately Controlled with MET Alone

被引：0
|
作者：
Bailey, Clifford J.
Gross, Jorge L.
Yadav, Manoj
Iqbal, Nayyar
Mansfield, Traci A.
List, James F.
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
988-P
引用
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [31] BAYESIAN NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN AND SULPHONYLUREA (MET plus SU)
    Pacou, M.
    Taieb, V
    Abrams, K. R.
    Diels, J.
    van Sanden, S.
    Garg, M.
    Schroeder, M.
    Kaur, V
    Nielsen, A. T. N.
    Nuhoho, S.
    Neslusan, C.
    Hemels, M.
    VALUE IN HEALTH, 2013, 16 (07) : A431 - A431
  • [32] Long-term (2-year) effects on HOMA-%S, an estimate of insulin sensitivity, of pioglitazone, gliclazide and metformin as add-on therapies in patients with T2DM
    Urquhart, R
    Tan, MH
    Mariz, S
    Moules, I
    Edwards, G
    DIABETES, 2004, 53 : A150 - A150
  • [33] 22. Long-Term Safety and Efficacy of Dapagliflozin in Patients with T2DM and Cardiovascular Disease (106-OR)
    William T. Cefalu
    Lawrence A. Leiter
    Eva Johnsson
    Jennifer Sugg
    Ingrid Gause-Nilsson
    Nederlands Tijdschrift voor Diabetologie, 2015, 13 (3) : 77 - 78
  • [34] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [35] Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes inadequately controlled with metformin and dapagliflozin: a randomised, double-blind, and placebo-controlled study
    Cho, Y.
    Kim, K. -S.
    Lee, B. -W.
    Hong, J.
    Yu, J.
    Lim, S.
    Kim, Y.
    Lee, C.
    Kim, S.
    Kwak, S.
    Lee, W.
    DIABETOLOGIA, 2024, 67 : S322 - S323
  • [36] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [37] Randomised, double-blind trial of dual add-on saxagliptin plus dapagliflozin vs saxagliptin or dapagliflozin add-on alone in poorly controlled type 2 diabetes on metformin
    Hansen, L.
    Zee, P.
    Li, Y.
    Cook, W.
    Hirshberg, B.
    Iqbal, N.
    Rosenstock, J.
    DIABETOLOGIA, 2014, 57 : S8 - S8
  • [38] A HEALTH ECONOMIC ANALYSIS OF THE LONG-TERM OUTCOMES AND COSTS ASSOCIATED WITH USING CANAGLIFLOZIN VERSUS SITAGLIPTIN AS AN ADD-ON TO METFORMIN (MET) IN MEXICO
    Teschemaker, A. R.
    Neslusan, C.
    Puig, A.
    Valencia, A.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2013, 16 (07) : A689 - A690
  • [39] The Efficacy and Safety of Imeglimin as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
    Fouqueray, Pascale
    Pirags, Valdis
    Inzucchi, Silvio
    Bailey, Clifford J.
    Schernthaner, Guntram
    Diamant, Michaela
    Lebovitz, Harold E.
    DIABETES, 2012, 61 : A257 - A257
  • [40] Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
    Aronson, Ronnie
    Frias, Juan
    Goldman, Allison
    Darekar, Amanda
    Lauring, Brett
    Terra, Steven G.
    DIABETES OBESITY & METABOLISM, 2018, 20 (06): : 1453 - 1460
12345